Cargando…

Serum phosphorylated neurofilament heavy chain as a diagnostic biomarker for progressive myelomalacia in dogs with thoracolumbar intervertebral disc herniation

BACKGROUND: Serum phosphorylated neurofilament‐heavy chain (pNF‐H) has not been longitudinally evaluated in dogs that develop progressive myelomalacia (PMM) after Type I intervertebral disc herniation (IVDH). OBJECTIVES: To determine if serum pNF‐H concentrations would predict outcome of neuroligica...

Descripción completa

Detalles Bibliográficos
Autores principales: Murthy, Vishal D., Li, Chai‐Fei, Hicks, Jill, Kroll, Jacqueline, Giuffrida, Michelle, Dickinson, Peter, Toedebusch, Christine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478056/
https://www.ncbi.nlm.nih.gov/pubmed/34476832
http://dx.doi.org/10.1111/jvim.16251
_version_ 1784575976390262784
author Murthy, Vishal D.
Li, Chai‐Fei
Hicks, Jill
Kroll, Jacqueline
Giuffrida, Michelle
Dickinson, Peter
Toedebusch, Christine M.
author_facet Murthy, Vishal D.
Li, Chai‐Fei
Hicks, Jill
Kroll, Jacqueline
Giuffrida, Michelle
Dickinson, Peter
Toedebusch, Christine M.
author_sort Murthy, Vishal D.
collection PubMed
description BACKGROUND: Serum phosphorylated neurofilament‐heavy chain (pNF‐H) has not been longitudinally evaluated in dogs that develop progressive myelomalacia (PMM) after Type I intervertebral disc herniation (IVDH). OBJECTIVES: To determine if serum pNF‐H concentrations would predict outcome of neuroligical disease in dogs with acute, severe thoracolumbar myelopathy secondary to Type I IVDH. ANIMALS: Thirty‐nine client‐owned dogs with thoracolumbar myelopathy secondary to IVDH. METHODS: Prospective controlled cohort study. Serum was collected from dogs undergoing hemilaminectomy at multiple timepoints. Final neurological status was established at 12 months and groups were stratified accordingly. Comparisons between outcome and pNF‐H concentration at each timepoint was examined using Kruskal‐Wallis analysis of variance on ranks and receiver operator characteristics curve analysis. RESULTS: Median serum pNF‐H concentrations were not significantly different between deep pain negative dogs that did or did not recover at any timepoint (baseline: 0.37 ng/mL [0‐0.9 ng/mL] vs 0 ng/mL [0‐0.9 ng/mL], P > 1; 24 hours: 1.25 ng/mL [0.35‐7.23 ng/mL] vs 1.53 ng/mL [0‐11.94 ng/mL], P > 1; 48 hours: 1.22 ng/mL [0.63‐6.62 ng/mL] vs 2.12 ng/mL [0‐20.72 ng/mL], P >  1; 72 hours: 2.77 ng/mL [1.33‐6.62 ng/mL] vs 16.69 ng/mL [4.02‐40.12 ng/mL], P >  1). Dogs that developed PMM had significantly higher serum pNF‐H concentrations after surgery compared to all other cohorts at 24 hours: 39.88 ng/mL (25.74‐50.68 ng/mL); P < .05 and 72 hours: 223.9 ng/mL (155.4‐263.7 ng/mL); P < .05. A serum pNF‐H concentration ≥31.39 ng/mL was 83.33% sensitive and 100% specific for identifying PMM in this cohort. CONCLUSIONS AND CLINICAL IMPORTANCE: Serum pNF‐H is a promising biomarker for antemortem diagnosis of PMM in dogs with acute, severe thoracolumbar myelopathy secondary to Type I IVDH.
format Online
Article
Text
id pubmed-8478056
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-84780562021-10-01 Serum phosphorylated neurofilament heavy chain as a diagnostic biomarker for progressive myelomalacia in dogs with thoracolumbar intervertebral disc herniation Murthy, Vishal D. Li, Chai‐Fei Hicks, Jill Kroll, Jacqueline Giuffrida, Michelle Dickinson, Peter Toedebusch, Christine M. J Vet Intern Med SMALL ANIMAL BACKGROUND: Serum phosphorylated neurofilament‐heavy chain (pNF‐H) has not been longitudinally evaluated in dogs that develop progressive myelomalacia (PMM) after Type I intervertebral disc herniation (IVDH). OBJECTIVES: To determine if serum pNF‐H concentrations would predict outcome of neuroligical disease in dogs with acute, severe thoracolumbar myelopathy secondary to Type I IVDH. ANIMALS: Thirty‐nine client‐owned dogs with thoracolumbar myelopathy secondary to IVDH. METHODS: Prospective controlled cohort study. Serum was collected from dogs undergoing hemilaminectomy at multiple timepoints. Final neurological status was established at 12 months and groups were stratified accordingly. Comparisons between outcome and pNF‐H concentration at each timepoint was examined using Kruskal‐Wallis analysis of variance on ranks and receiver operator characteristics curve analysis. RESULTS: Median serum pNF‐H concentrations were not significantly different between deep pain negative dogs that did or did not recover at any timepoint (baseline: 0.37 ng/mL [0‐0.9 ng/mL] vs 0 ng/mL [0‐0.9 ng/mL], P > 1; 24 hours: 1.25 ng/mL [0.35‐7.23 ng/mL] vs 1.53 ng/mL [0‐11.94 ng/mL], P > 1; 48 hours: 1.22 ng/mL [0.63‐6.62 ng/mL] vs 2.12 ng/mL [0‐20.72 ng/mL], P >  1; 72 hours: 2.77 ng/mL [1.33‐6.62 ng/mL] vs 16.69 ng/mL [4.02‐40.12 ng/mL], P >  1). Dogs that developed PMM had significantly higher serum pNF‐H concentrations after surgery compared to all other cohorts at 24 hours: 39.88 ng/mL (25.74‐50.68 ng/mL); P < .05 and 72 hours: 223.9 ng/mL (155.4‐263.7 ng/mL); P < .05. A serum pNF‐H concentration ≥31.39 ng/mL was 83.33% sensitive and 100% specific for identifying PMM in this cohort. CONCLUSIONS AND CLINICAL IMPORTANCE: Serum pNF‐H is a promising biomarker for antemortem diagnosis of PMM in dogs with acute, severe thoracolumbar myelopathy secondary to Type I IVDH. John Wiley & Sons, Inc. 2021-09-02 2021 /pmc/articles/PMC8478056/ /pubmed/34476832 http://dx.doi.org/10.1111/jvim.16251 Text en © 2021 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle SMALL ANIMAL
Murthy, Vishal D.
Li, Chai‐Fei
Hicks, Jill
Kroll, Jacqueline
Giuffrida, Michelle
Dickinson, Peter
Toedebusch, Christine M.
Serum phosphorylated neurofilament heavy chain as a diagnostic biomarker for progressive myelomalacia in dogs with thoracolumbar intervertebral disc herniation
title Serum phosphorylated neurofilament heavy chain as a diagnostic biomarker for progressive myelomalacia in dogs with thoracolumbar intervertebral disc herniation
title_full Serum phosphorylated neurofilament heavy chain as a diagnostic biomarker for progressive myelomalacia in dogs with thoracolumbar intervertebral disc herniation
title_fullStr Serum phosphorylated neurofilament heavy chain as a diagnostic biomarker for progressive myelomalacia in dogs with thoracolumbar intervertebral disc herniation
title_full_unstemmed Serum phosphorylated neurofilament heavy chain as a diagnostic biomarker for progressive myelomalacia in dogs with thoracolumbar intervertebral disc herniation
title_short Serum phosphorylated neurofilament heavy chain as a diagnostic biomarker for progressive myelomalacia in dogs with thoracolumbar intervertebral disc herniation
title_sort serum phosphorylated neurofilament heavy chain as a diagnostic biomarker for progressive myelomalacia in dogs with thoracolumbar intervertebral disc herniation
topic SMALL ANIMAL
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478056/
https://www.ncbi.nlm.nih.gov/pubmed/34476832
http://dx.doi.org/10.1111/jvim.16251
work_keys_str_mv AT murthyvishald serumphosphorylatedneurofilamentheavychainasadiagnosticbiomarkerforprogressivemyelomalaciaindogswiththoracolumbarintervertebraldischerniation
AT lichaifei serumphosphorylatedneurofilamentheavychainasadiagnosticbiomarkerforprogressivemyelomalaciaindogswiththoracolumbarintervertebraldischerniation
AT hicksjill serumphosphorylatedneurofilamentheavychainasadiagnosticbiomarkerforprogressivemyelomalaciaindogswiththoracolumbarintervertebraldischerniation
AT krolljacqueline serumphosphorylatedneurofilamentheavychainasadiagnosticbiomarkerforprogressivemyelomalaciaindogswiththoracolumbarintervertebraldischerniation
AT giuffridamichelle serumphosphorylatedneurofilamentheavychainasadiagnosticbiomarkerforprogressivemyelomalaciaindogswiththoracolumbarintervertebraldischerniation
AT dickinsonpeter serumphosphorylatedneurofilamentheavychainasadiagnosticbiomarkerforprogressivemyelomalaciaindogswiththoracolumbarintervertebraldischerniation
AT toedebuschchristinem serumphosphorylatedneurofilamentheavychainasadiagnosticbiomarkerforprogressivemyelomalaciaindogswiththoracolumbarintervertebraldischerniation